Patents by Inventor George Kopsidas

George Kopsidas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110206686
    Abstract: The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA).
    Type: Application
    Filed: October 3, 2008
    Publication date: August 25, 2011
    Inventors: Gary Peter Bembridge, Jane Elizabeth Clarkson, Jonathan Henry Ellis, Paul Andrew Hamblin, George Kopsidas, Alan Peter Lewis, Ruth Mcadam
  • Publication number: 20100221260
    Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder.
    Type: Application
    Filed: December 14, 2006
    Publication date: September 2, 2010
    Inventors: Stephanie Jane Clegg, Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin, George Kopsidas, Ruth McAdam, Rabinder Kumar Prinjha
  • Publication number: 20100144600
    Abstract: The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduce binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The OVPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.
    Type: Application
    Filed: September 11, 2009
    Publication date: June 10, 2010
    Applicants: Arana Therapeutics Limited
    Inventors: Anthony Roberts, George Kopsidas, Gregory Coia, Merilyn Sleigh, Vincent Batori
  • Publication number: 20090311710
    Abstract: The use of RNA-replicases for introducing mutations into and selecting for improved RNA molecules is described. The use of ribavirin, or a derivative/analogue thereof, in methods for introducing one or more mutations during replication or transcription of a target nucleic acid molecule is also described. These methods can be used to screen for nucleic acids, or proteins encoded thereby, with altered or new activity. Also provided are kits comprising ribavirin, or a derivative/analogue thereof, for use in mutagenesis procedures.
    Type: Application
    Filed: July 15, 2009
    Publication date: December 17, 2009
    Inventors: Gregory COIA, George Kopsidas, Merilyn Sleigh
  • Patent number: 7612169
    Abstract: The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduced binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The OVPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: November 3, 2009
    Assignee: EvoGenix, Ltd.
    Inventors: Anthony Roberts, George Kopsidas, Gregory Coia, Merilyn Sleigh, Vincent Batori
  • Publication number: 20090123479
    Abstract: The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA).
    Type: Application
    Filed: October 3, 2008
    Publication date: May 14, 2009
    Inventors: Gary Peter Bembridge, Jane Elizabeth Clarkson, Jonathan Henry Ellis, Paul Andrew Hamblin, George Kopsidas, Alan Peter Lewis, Ruth McAdam
  • Publication number: 20060189528
    Abstract: The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduce binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The OVPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.
    Type: Application
    Filed: December 13, 2005
    Publication date: August 24, 2006
    Inventors: Anthony Roberts, George Kopsidas, Gregory Coia, Merilyn Sleigh, Vincent Batori
  • Publication number: 20050266453
    Abstract: The use of RNA-replicases for introducing mutations into and selecting for improved RNA molecules is described. The use of ribavirin, or a derivative/analogue thereof, in methods for introducing one or more mutations during replication or transcription of a target nucleic acid molecule is also described. These methods can be used to screen for nucleic acids, or proteins encoded thereby, with altered or new activity. Also provided are kits comprising ribavirin, or a derivative/analogue thereof, for use in mutagenesis procedures.
    Type: Application
    Filed: April 26, 2005
    Publication date: December 1, 2005
    Inventors: Gregory Coia, George Kopsidas, Merilyn Sleigh